triumph trial retatrutide Looking forward to when #retatrutide's Phase 3 results will become available. There are are 4 planned trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease A summary slide of the

However, retatrutide's mid-stage obesity trial only included 338 patients

Retatrutide activates three receptors simultaneously GLP-1, GIP, and glucagon

Data Availability The data sets generated or analyzed during this study are not publicly available due to the nature of the clinical data collected and the consent provided by patients

In the ECHO RCT [133], almost half of the subjects treated with weekly exenatide had a favorable treatment response with a reduction of BMI, while the other half did not respond to treatment, thus illustrating the need for an approach to address treatment nonresponse and to stratify patients with respect to predicted treatment response, using more potent GLP-1RAs and considering the use of GLP-1RAs in combination with other pharmacological approaches to treat HO

Support Blood Sugar Control : GLP-1 injections stabilize blood sugar by increasing insulin and lowering glucagon, which also helps reduce cravings

Longer duration: The week-long half-life means receptors are consistently activated rather than experiencing daily fluctuation